To further investigate the predictive utility of GALNT14-rs62139523 “A/G” genotype for favorable OS and PFS in intermediate-stage CRC patients undergoing surgical resection followed by 5-FU-based adjuvant chemotherapy, subgroup analyses were conducted using Cox proportional hazards models across various subgroups. The gene discussed is GALNT14; the disease is colorectal carcinoma.